These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 9257783)

  • 1. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis.
    Zenner HP; Baumgarten C; Rasp G; Fuchs T; Kunkel G; Hauswald B; Ring J; Effendy I; Behrendt W; Frosch PJ; Przybilla B; Brunner FX; Merk HF; Kapp A; Schnitker J; Wolf H
    J Allergy Clin Immunol; 1997 Jul; 100(1):23-9. PubMed ID: 9257783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens.
    Balda BR; Wolf H; Baumgarten C; Klimek L; Rasp G; Kunkel G; Müller S; Mann W; Hauswald B; Heppt W; Przybilla B; Amon U; Bischoff R; Becher G; Hummel S; Frosch PJ; Rustemeyer T; Jäger L; Brehler R; Luger T; Schnitker J
    Allergy; 1998 Aug; 53(8):740-8. PubMed ID: 9722222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
    Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
    Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study.
    Leynadier F; Banoun L; Dollois B; Terrier P; Epstein M; Guinnepain MT; Firon D; Traube C; Fadel R; André C
    Clin Exp Allergy; 2001 Jul; 31(7):988-96. PubMed ID: 11467988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial.
    Pfaar O; Klimek L
    Ann Allergy Asthma Immunol; 2008 Mar; 100(3):256-63. PubMed ID: 18426146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of preseasonal grass pollen immunotherapy in children.
    Eng PA; Reinhold M; Gnehm HP
    Allergy; 2002 Apr; 57(4):306-12. PubMed ID: 11906360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
    Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
    Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
    Panzner P; Petráš M; Sýkora T; Lesná IK; Liška M
    Allergy Asthma Proc; 2011; 32(2):142-50. PubMed ID: 21439167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial.
    Sharif H; Singh I; Kouser L; Mösges R; Bonny MA; Karamani A; Parkin RV; Bovy N; Kishore U; Robb A; Katotomichelakis M; Holtappels G; Derycke L; Corazza F; von Frenckell R; Wathelet N; Duchateau J; Legon T; Pirotton S; Durham SR; Bachert C; Shamji MH
    J Allergy Clin Immunol; 2019 Sep; 144(3):738-749. PubMed ID: 30844425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis.
    Bozek A; Kolodziejczyk K; Warkocka-Szoltysek B; Jarzab J
    Am J Rhinol Allergy; 2014; 28(5):423-7. PubMed ID: 25198030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
    Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
    J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
    Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
    J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study.
    de Blay F; Barnig C; Kanny G; Purohit A; Leynadier F; Tunon de Lara JM; Chabane H; Guérin L;
    Ann Allergy Asthma Immunol; 2007 Nov; 99(5):453-61. PubMed ID: 18051216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial.
    Caffarelli C; Sensi LG; Marcucci F; Cavagni G
    Allergy; 2000 Dec; 55(12):1142-7. PubMed ID: 11117271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
    Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
    J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sublingual swallow immunotherapy in children with rye grass pollen allergic rhinitis: a double-blind placebo-controlled study.
    Ahmadiafshar A; Maarefvand M; Taymourzade B; Mazloomzadeh S; Torabi Z
    Iran J Allergy Asthma Immunol; 2012 Jun; 11(2):175-81. PubMed ID: 22761191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.